TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: 5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Homo sapiens (Human))
Peloton Therapeutics
US Patent
Peloton Therapeutics
US Patent
Affinity DataIC50: <5nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair